Dr Ian Irving

Clinical Haematologist
Become a Patient

Dr Ian Irving has a genuine commitment to each patient he cares for and the communities he is part of. He brings a calm, positive and approachable demeanour to his practice. Dr Irving’s patients benefit from his profound understanding of cancer care and reassurance in achieving the best possible outcome.


Dr Ian Irving is an experienced clinical haematologist at Icon Cancer Centre Wesley and Icon Cancer Centre Mackay, and is Icon Group’s Chief Medical Officer. He graduated from the University of Queensland in 1991 with a Bachelor of Medicine and Bachelor of Surgery. He became a fellow of the Royal Australian College of Physicians in 2000 and of the Royal College of Pathologists of Australia in 2001. Dr Irving has previously been appointed in the public system as the director of haematology and bone marrow transplantation at the Townsville Hospital. From 2006 – 2013, he was the clinical director of the Institute of Cancer, during which time he was responsible for consolidating and expanding tertiary level cancer care in North Queensland.

His expertise covers a very broad range of haematological disorders, including bone marrow transplantation (autologous and allogeneic), acute leukaemia, lymphoma, obstetric haematology, general haematology, disorders of iron metabolism and laboratory haematology. This expertise comes from his extensive training and consultant posts in Brisbane, Perth and overseas in the positions of haematologist at Sullivan Nicolaides and St John of God Pathology, consultant haematologist at the Royal Brisbane Hospital, transplant physician (locum) at St James Hospital Dublin, consultant haematologist at National Maternity Hospital (Dublin), and haematologist at PathCentre WA.

Although retaining broad haematological knowledge, Dr Irving has a special clinical interest in lymphoma, myelodysplasia, multiple myeloma, myeloproliferative neoplasms and stem cell transplantation. He has sat on national and international committees and advisory boards, focusing on haematological disorders such as chronic myeloid leukaemia, myelofibrosis, myelodysplasia, lymphoma and bone marrow transplantation.

Dr Irving is a strong advocate for clinical trial research, participating in phase I/II and III multicentre clinical trials. Dr Irving has many leadership qualities in addition to his clinical skills, having performed senior administrative roles in haematology and cancer.

Affiliations & Memberships

  • Royal Australian College of Physicians (RACP)
  • Royal College of Pathologists of Australasia (RCPA)
  • Australian Medical Association (AMA)
  • Haematology Society of Australia and NZ (HSANZ)
  • European Haematology Association (EHA)
  • American Society of Clinical Oncology (ASCO)
  • Australasian Society for Blood Transfusion (ASBT)
  • Australasian Society for Thrombosis & Haemostasis (ASTH)
  • Bone Marrow Transplant Association of Australia and NZ (BMTSANZ)
  • Australian Leukaemia & Lymphoma Study Group (ALLG)
  • Townsville Medical Staff Society (TMSS)

Special Interests

Dr Ian Irving accepts referrals for malignant and non-malignant blood disorders, with a special clinical interest in:
  • Haematology
  • Lymphoma
  • Multiple myeloma
  • Myelodysplasia
  • Myeloproliferative neoplasms
  • Stem cell transplantation

Icon Locations

Wesley View centre
Mackay View centre


  • Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia. Kenneth F. Bradstock, Alec Morley, Karen Byth, Jeff Szer, Ian Prosser, Paul Cannell, Ian Irving, John F. Seymour. Contemporary Clinical Trials Communications, Volume 4, 15 December 2016, 9-13

  • An imatinib-only window followed by imatinib and chemotherapy for Philadelpha chromosome-postive leukaemia:long term results of the CMLALL1 trial. Lickliter JD, Taylor K, Szer J, Grigg A, Arthur C, Hughes TP, Durrant S, Filshie R, Irving I, Seldon M, Ellacott J, Boyd AW, D’Rozario J, Rooney K, Lynch K, Bradstock K; Australiasian Leukaemia and Lymphoma Group. Leuk Lymphoma 2015 Mar; 56 (3): 630-638

  • Screening whole spine magnetic resonance imaging in multiple myeloma. Wight J, Stillwell A, Morris E, Grant B, Lai HC, Irving I. Internal Med J. 2015 Jul; 45 (7): 762-765

  • Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Hocking J, Schwarer AP, Gasiorowski R, Patil S, Avery S, Gibson J, Iland H, Ho PJ, Joshua D, Muirhead J, Lai H, Irving I. Leuk Lymphoma 2014 Dec; 55 (12): 2201-2207

  • Isolated intracranial myeloid sarcoma. Hodges G, Lai HC, Irving I, Macloud M, Korah I, Ramuz O, Morris E. Pathology 2012 Oct; 44 (6): 571-574